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Abstract  
Interferon lambda (IFNλ) is important for epidermal defence against viruses.  It is produced 
by, and acts on, keratinocytes, whereas fibroblasts were previously considered to be 
unresponsive to this type III IFN.  
Herein we report novel findings revealing cell type-specific differences in IFNλ signalling and 
function in skin resident cells. In dermal fibroblasts, IFNλ induces the expression of MxA, a 
potent antiviral factor, but not other interferon signature genes as it does in primary 
keratinocytes. In contrast to its effect on keratinocytes, IFNλ does not phosphorylate STAT1 
in fibroblasts, but instead activates MAPK. Accordingly, inhibition of MAPK activation (p38 
and p42/44) blocks expression of MxA protein in fibroblasts but not in keratinocytes. 
Functionally, IFNλ inhibited proliferation in keratinocytes but not in fibroblasts. Moreover, 
IFNλ upregulated the expression of TGFβ1-induced collagens in fibroblasts. Taken together, 
our findings identify primary human dermal fibroblasts as responder cells to IFNλ. Our study 
shows cutaneous cell type-specific IFN signalling and suggests that IFNλ, whilst important 
for epidermal anti-viral competence, may also have a regulatory role in the dermal 
compartment balancing type I IFN-induced inhibition of tissue repair processes. 
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Introduction   
Fibroblasts and keratinocytes are the main tissue cell types found in the dermis and 
epidermis respectively. While many recent studies have identified the immunological role of 
keratinocytes, the role of dermal fibroblasts in host defence and inflammatory diseases are 
only beginning to emerge. Furthermore,  dermal fibroblasts synthesise extracellular matrix 
including collagens (Xu et al., 2009) and thus play an important role in maintaining skin 
structure and wound healing. Interferon lambda (IFNλ) is a type III IFN comprising four 
members, IFNλ1 (IL-29), IFNλ2 (IL-28A), IFNλ3 (IL-28B) and IFNλ4 (Kotenko et al., 2003; 
Prokunina-Olsson et al., 2013; Sheppard et al., 2003).  IFNλ belongs to the IL-10 family of 
cytokines along with IL-10, IL-19, IL-20, IL-22, IL-24 and IL-26. IFNλ uses the heterologous 
receptor complex comprising IFNλR1 (also known as IL-28Rα1) and the ubiquitously 
expressed IL-10 receptor 2 (IL-10Rβ) which is also used by IL-10, IL-22 and IL-26 as a 
second receptor subunit (Kotenko et al., 2003; Sheppard et al., 2003). IFNλR1 is the 
signalling subunit and so its presence determines cellular responsiveness. Although IFNλ is 
structurally related to IL-10, it resembles type I IFNs in its antiviral and antiproliferative 
functions (Miknis et al., 2010). They both signal mainly through the recruitment and 
activation of members of the janus family of kinases, JAK1/TYK2 leading to the 
phosphorylation of signal transducer and activator of transcription (STAT) 1/2 and 
subsequently to induction of  a set of downstream genes known as IFN-stimulated genes 
(ISGs) such as Myxovirus protein A (MxA), Guanylate binding protein 1 (GBP-1), 2,5-
oligoadenylate synthetase (2,5-OAS) and IFN inducible protein 16 (IFI16) with potent 
antiviral activities (Ank et al., 2008; Sommereyns et al., 2008). Beyond JAK/STAT activation,  
type I IFNs have also been found to activate MAPK (p38 and ERK (p42/p44) MAPK) which 
allows for full activation of downstream ISGs (Nguyen et al., 2000; Uddin et al., 2000); and 
possibly downstream phosphorylation of STAT1 on serine 727 (Goh et al., 1999). 
Type I IFNs signal through membrane associated IFNAR1 and IFNAR2 (Lutfalla et al., 
1995). While the two subunits of IFNAR are present on all nucleated cell types, IFNλR1 is 
selectively expressed and functional in certain cell types only (Dickensheets et al., 2013; 
4 
 
Kotenko et al., 2003; Witte et al., 2009; Zahn et al., 2010). Witte et al. described the 
presence of IL-28Rα1 mRNA expression in human dermal fibroblasts. However, it was 
observed that these cells were unresponsive to IFNλ, and this was attributed to the very low 
expression level of the receptor in these cells (Lasfar et al., 2011; Witte et al., 2009).  
IFNλ is the main IFN produced by keratinocytes and production of varying amounts of this 
cytokine has been reported also in other cell types (Wolk et al., 2013; Yin et al., 2012; Zahn 
et al., 2010). Keratinocytes are susceptible to IFNλ1 and this cytokine substantially 
contributes to the antiviral competence of the human epidermis (Wolk et al., 2013). Apart 
from antiviral properties, both types I and III IFNs are known for their pro-apoptotic and anti-
proliferative activities (Abushahba et al., 2010; Maher et al., 2008; Steen and Gamero, 
2010). These activities have been linked to the ability of IFNs to phosphorylate STAT1 
(Zitzmann et al., 2006). High expression of ISGs such as CXCL9, CXCL10, MxA and GBP-1 
has been reported in interface dermatitis conditions such as cutaneous lupus erythematosus 
(CLE) and here increased expression is linked with disease severity (Naschberger et al., 
2010; Wenzel et al., 2005).  
In this study, we sought to understand if human dermal fibroblasts are responsive to IFNλ1 
through the activation of STAT1 and subsequent downstream induction of ISGs. We also 
wanted to understand the role of this cytokine in maintenance of skin integrity with regard to 
collagen expression and proliferation of skin resident cells. 
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Results 
IFNλR1 is expressed by human dermal fibroblasts 
In order to confirm the expression of IFNλR1 in fibroblasts and to investigate its regulation, 
fibroblasts were stimulated for 4 or 16 hours for analysis of mRNA and protein expression, 
respectively. mRNA expression was measured by qPCR  and protein expression was 
measured by Western blotting and flow cytometry. We found that IFNλR1 was expressed in 
dermal fibroblasts and was upregulated in the presence of IFNα (Figure 1a-e and S1).  
 
IFNλ induces significant expression of MxA in human dermal fibroblasts 
To investigate if IFNλR1 is functional in human dermal fibroblasts, cells were treated with 
rhIFNλ or rhIFNα (positive control) for 4 or 24 hours. mRNA expression of ISGs was 
quantified using qRT-PCR. We found significant expression of MxA but not GBP-1 (Figure 
2a-d) or OAS2 (Figure S2) after 4 and 24 hours of IFNλ1 treatment. As expected, when 
compared to IFNλ1, IFNα induced significantly higher expression of MxA and GBP-1 after 4 
hours of treatment (Figure 2a-d). However, while the expression of MxA remained high after 
24 hours of treatment with IFNα, GBP-1 expression dropped significantly over this time 
period (Figure 2b/d). In fibroblasts, IFNα appeared to induce higher upregulation of MxA as 
compared to GBP-1 (Figure 2a-d). Dose-dependent effect of IFNλ1 on MxA expression in 
dermal fibroblasts was also carried out after 4 hours of treatment with different 
concentrations of IFNλ1 (Figure S3).   
 
IFNα and IFNλ induce ISG expression in human primary keratinocytes 
We compared our findings on ISGs expression in fibroblasts with the expression pattern in 
human primary keratinocytes. The responsiveness of keratinocytes to both type I and III 
IFNs is well documented (Bachmann et al., 2013; Zahn et al., 2011; Zahn et al., 2010).  We 
found that both IFNα and IFNλ1 induced significant mRNA expression of MxA, OAS2 and 
GBP-1 with a higher induction of MxA as compared to OAS2 and GBP-1 (Figure 2e-h and 
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Figure S2). Interestingly, we observed a different time kinetic for the ISG response to IFNα 
as compared to IFNλ1. IFNα showed a strong upregulation of MxA and GBP-1 at 6 hours, 
while IFNλ1 stimulation resulted in a strong increase in MxA and GBP-1 expression between 
6 and 24 hours. This suggests that IFNλ1 stimulation may result in more delayed and/or 
longer lasting effects (Figure 2e-h) as previously observed in hepatocytes (Bolen et al., 
2014).  
 
IFNλ activates p38 and ERK MAPKs but not STAT1 (Tyr701) in human dermal 
fibroblasts 
Having established that dermal fibroblasts respond to IFNλ1, we were interested in 
understanding their mechanism of action. To achieve this, dermal fibroblasts were treated 
with either IFNλ1 or IFNα for different time points and protein phosphorylation was 
determined using western blotting. As expected, IFNα-induced STAT1 phosphorylation with 
maximal phosphorylation detected after 30 minutes of stimulation (Figure 3a). However, we 
failed to observe any STAT1 phosphorylation in IFNλ1 treated cells in any of the time points 
investigated. Various groups have reported that phosphorylation of p38 may be necessary 
for full activation of STAT1 dependent genes (Goh et al., 1999; Platanias, 2003; Uddin et al., 
2000). We therefore investigated the ability of IFNλ1 to induce the phosphorylation of p38 in 
dermal fibroblasts and clearly found activation of this MAPK (Figure 3a). We confirmed that 
IFNα treatment resulted in p38 phosphorylation in addition to STAT1 phosphorylation (Figure 
3a). Furthermore, we found that both IFNα and IFNλ1 induced phosphorylation of ERK, but 
not the Akt (p60) (data not shown) pathway in dermal fibroblasts. . As expected, we found 
that both IFNα and IFNλ1 induced STAT1 phosphorylation in primary keratinocytes (Figure 
3b). However, we did not observe clear IFNλ dependent activation of either the p38 or ERK 
pathway upon treatment with IFNs (Figure 3b). 
 
P38 and ERK inhibitors attenuate IFNλ1-induced MxA protein expression  
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We sought to understand if the activation of P38 and ERK was responsible for the induction 
of MxA expression in dermal fibroblasts. To investigate this, fibroblasts were pretreated with 
p38 (10 μM SB203580) or ERK inhibitor (30 μM PD98059 or 10 μM U0126) for 1 hour before 
treatment with IFNλ1 or IFNα. mRNA and protein expression were measured by qRT-PCR 
and Western blotting respectively. Interestingly, our results showed that the expression of 
MxA was not regulated at the mRNA level by the MAPK inhibitors (Figure 4a/b). However, 
the presence of either the p38 or ERK inhibitor abrogated IFNλ1-induced MxA protein 
production (Figure 4c). We did not observe a decrease in IFNα-induced MxA protein 
production in fibroblasts in the presence of SB203580, PD98059 (not shown) or U0126 
(Figure 4d). We also analysed whether MAPKs played a role in IFNλ1-induced MxA protein 
expression in human primary keratinocytes. We failed to find a significant effect of p38 or 
ERK inhibition on IFNλ1 and IFNα-induced MxA protein production in keratinocytes (Figure 
4e). 
 
IFNλ enhances collagen expression in human dermal fibroblasts  
As conditions with high type I IFN expression can be linked to impaired healing responses, 
we investigated whether IFNλ1 had any influence on collagen expression. Fibroblasts were 
treated with IFNλ1, IFNα, TGFβ1 or a combination of IFN and TGFβ1. TGFβ1 was used as a 
control, given its well described stimulation of fibroblast proliferation and collagen synthesis. 
We measured Col1A1, Col3A1, Col4A2 and Col7A1 using qRT-PCR. There was no 
difference in collagen expression after 6 hours of stimulation with these cytokines (data not 
shown). However, after 24 hours of treatment, TGFβ1 significantly induced the expression of 
these collagens. Combined treatment of cells with IFNλ1 and TGFβ1 resulted in a 
significantly higher expression of these collagens (except for Col3A1) than with either 
treatment alone (Figure 5a-d). To investigate which of the MAPK pathways may be 
responsible for the synergy, we treated cultured dermal fibroblasts with either IFNλ1 or 
TGFβ1 or both together for 30 minutes and checked for the phosphorylation of p38 and ERK 
by Western blotting. We found that both IFNλ1 and TGFβ1 activated the p38 and ERK 
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pathways independently. Interestingly, we observed a clear synergistic effect between IFNλ1 
and TGFβ1 on the activation of the p38 pathway. The effect is less clear with the ERK 
pathway (Figure S4). This suggests that the p38 pathway may be responsible for the 
synergistic effect observed on collagen expression. 
 
IFNλ has potent anti-proliferative activity in primary keratinocytes but not in dermal 
fibroblasts  
The anti-proliferative effect of IFNλ1 on HaCaT keratinocyte cell lines has been described 
(Maher et al., 2008). We aimed to compare the effect of both IFNλ1 and IFNα on primary 
skin cells. Keratinocytes and fibroblasts were stained with cell tracer dye and subsequently 
stimulated with either IFNλ or IFNα for 72 hours. As expected, both IFNs clearly reduced 
keratinocyte proliferation (Figure 6a/b). By contrast, we observed that IFNα but not IFNλ1 
inhibited dermal fibroblast proliferation (Figure 6c/d). TGFβ1, known to induce fibroblast 
proliferation, was used as positive control (Figure 6c/d).  
We also investigated the effects of IFNλ1 and IFNα on “gap” closure in monolayer cultures of 
dermal fibroblasts. We observed that IFNλ1 improved gap closure in fibroblasts while IFNα 
delayed gap closure after 48 hours of stimulation in comparison to the untreated cells 
(Figure S5).  
 
 
 
 
 
 
 
 
 
Discussion 
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Type I and III, innate IFNs were initially identified for their potent antiviral activities 
(MacMicking, 2012; Sadler and Williams, 2008). In addition, IFNs also have 
immunoregulatory, anti-proliferative and pro-apoptotic properties; they have been identified 
as potential anticancer drugs (Abushahba et al., 2010; Witte et al., 2010). However, they are 
also important mediators in the pathogenesis of autoimmune diseases such as cutaneous 
lupus erythematosus (Meyer, 2009; Ronnblom and Eloranta, 2013). MxA is a highly 
inducible ISG and one of the most potent anti-viral factors capable of blocking early 
replication events of different RNA and DNA viruses (Sadler and Williams, 2008). 
Type III IFN is the most recently described group of IFNs. Expression of their specific 
receptor was thought to be restricted mainly to epithelial cells (keratinocytes) and 
hepatocytes. There is, however, emerging evidence that IFNλR1 is also present and 
functional on hematopoietic cells (Dai et al., 2009; Liu et al., 2011; Mennechet and Uze, 
2006; Yin et al., 2012). There are reports identifying MAPKs as regulators of IFN 
downstream activities (Gough et al., 2008; Uddin et al., 2000; van Boxel-Dezaire et al., 
2006) and the importance of different (non JAK) kinases activated in response to IFNs has 
been speculated before to contribute to cell-type and IFN subtype specific responses (van 
Boxel-Dezaire et al., 2006). The main novelty of our findings is that we show a distinct 
signalling and thus also functional response of primary human fibroblasts to IFNλ which is 
different from the response of these cells to type I IFN and which is clearly different from the 
response of epidermal cells. Indeed, keratinocytes show a similar signalling and functional 
response to both type I and type III IFNs which is characterised by a STAT1-dependent 
upregulation of a broad range of ISGs. Dermal fibroblasts were considered unresponsive to 
IFNλ (Abushahba et al., 2010). We here show that human fibroblasts indeed respond to 
IFNλ1 treatment with significant expression of MxA mRNA and protein. In line with our 
findings, a recent study has reported the responsiveness of CMV infected foreskin fibroblast 
to IFNλ3 (Egli et al., 2014). It is well documented that types I and III IFNs induce similar sets 
of ISGs in many cell types (Ank et al., 2008; Sommereyns et al., 2008). However, in 
fibroblasts, we failed to observe significant expression of GBP-1 (Fig. 2) or other ISGs upon 
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IFNλ1 treatment. The inability of IFNλ1 to activate STAT1 (Tyr701) in fibroblasts was 
unexpected as this is the known canonical pathway for the induction of downstream ISG 
genes. However, our findings on IFNλ1 induced activation of both p38 and ERK suggest that 
the MAPK pathway may be an alternative for the induction of MxA by IFNλ in fibroblasts. It 
has been suggested that IFNα-induced phosphorylation of MAPKs and STAT1 are 
independent of each other; however, they work in tandem to ensure full activation of ISGs (Li 
et al., 2004). It is interesting that the inhibition of p38 and ERK in IFNα treated dermal 
fibroblasts did not result in significant downregulation of MxA protein expression; although 
we observed a slight reduction in MxA production by primary keratinocytes following 
inhibition of ERK but not p38. Activation of PI3K-AKT and Raf-MEK-ERK pathways by IFNλ1 
and IFNα in HepG2.2.15 cell lines has been reported (Chai et al., 2011), but we could not 
observe AKT pathway activation in our experiments. Our proposed mechanism of IFNα and 
IFNλ1 signalling in dermal fibroblasts is shown in Figure S6. To our surprise, we failed to 
observe any significant regulatory effects of the MAPK inhibitors at the transcriptional level 
suggesting that p38 and ERK inhibition results in posttransciptional regulation of MxA. 
Mechanisms of mRNA translation of ISGs have been reviewed (Joshi et al., 2010). Both the 
p38 and p42/44 MAPKs can control the activation of eIF4E and other substrates of MAPK 
interacting protein kinases 1 and 2 (Mnk1 and 2) which influence translation initiation (Joshi 
et al., 2010). Posttransriptional regulation of TNFα gene expression in the presence of p38 
inhibitor has been described (Clark et al., 2003). Future experiments will show the underlying 
mechanism of the posttranscriptional regulation observed for MxA in dermal fibroblasts. In 
this study, we have confirmed previous report that human dermal fibroblasts express IFNλR1 
(Witte et al., 2009) and that IFNα can upregulate its expression. The ability of IFNα to 
enhance the expression levels of IFNλR1 is evidence for a cross-talk between type I and 
type III IFNs (Duong et al., 2014).  
TGFβ1 is well known to induce collagen expression in fibroblasts. Types I, III, IV and VII 
collagens are the main ECM components, basement membrane zone and the anchoring 
fibrils at the dermal-epidermal junction (Tiedtke, 2007). We found that IFNλ1 potentiated the 
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TGFβ-associated induction of collagen I, but not collagen type III, expression. IFNγ, a type II 
IFN exhibited an inhibitory effect on TGFβ1-induced ECM or collagen deposition in primary 
human lung (Eickelberg et al., 2001) and in human foreskin fibroblasts (Ghosh et al., 2001). 
Of interest, keloid-derived dermal fibroblasts seem non-responsive to this IFNγ-dependent 
type I collagen regulation (Hasegawa et al., 2003).  Excessive secretion of type I collagen is 
linked with hypertrophic scar formation, while a sufficient amount of type III collagen may 
prevent scar formation (Oliveira et al., 2009). The net effect of IFNλ1 on cutaneous repair 
and healing responses is not clear yet and needs to be further investigated. The ability of 
IFNλ1 to upregulate the expression of type IV (Col4A2) and VII collagens (Col7A1) suggests 
that is may support basement membrane integrity (Nystrom et al., 2013).  
Our proliferation assay results in primary keratinocytes are consistent with the roles of IFNα 
and IFNλ1 as anti-proliferative agents. Our results show that IFNλ1 does not have an 
inhibitory effect on dermal fibroblasts’ proliferation and this may be due to its inability to 
induce STAT1 phosphorylation in these cells. In addition, the anti-proliferative ability of GBP-
1 on intestinal epithelial cells has been described (Capaldo et al., 2012) and IFNλ1 failed to 
induce GBP-1 expression in dermal fibroblasts.  
This study has shown that IFNλR1 is active in dermal fibroblasts through the activation of 
p38 and ERK pathways. We have shown that MxA induction by IFNλ1 occurs through a 
STAT1-independent pathway and this may also explain the role of this cytokine in 
enhancement of collagen expression and lack of anti-proliferative activity. Of note, IFNλ1 is 
highly expressed in both the scarring and the non-scarring subtype of CLE. Our data 
suggest that IFNλ1 may not be a key molecule in the reduced proliferation seen in dermal 
fibroblasts from discoid CLE patients (Nyberg et al., 2000).  
Egli et al have shown that in CMV treated foreskin derived fibroblast cell lines, IFNλ exerts 
an inhibitory action on IFNα induced antiviral activity (Egli et al., 2014). However, IFNα also 
enhances fibroblasts susceptibitlity to IFNλ. It is thus possible that IFNλ, while important for 
the epidermal antiviral competence, may exert important balancing and regulatory functions 
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in the dermal compartment. One of the effects could be to counteract the type I IFN induced 
impairment of repair mechanisms.  
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Materials and Methods 
Cytokine and antibodies  
Recombinant human (rh) IFNλ1 (100 ng/ml) was purchased from ebioscience (Hatfield, UK); 
rhIFNα2a (10 ng/ml; Merck Millipore, Merck Serono Ltd, Middlesex, UK), rhTGFβ1 (5 ng/ml; 
Peprotech EC Ltd, London, UK). Anti-human (rabbit phospho p38, mouse phospho ERK, 
mouse ERK, rabbit p38, rabbit phospho STAT1 and rabbit STAT1) antibodies were 
purchased from Cell signalling Technology (Leiden, The Netherlands); anti-human (rabbit 
MxA, rabbit IFNλR1 and mouse GAPDH) antibodies were purchased from Abcam 
(Cambridge, UK) and Santa Cruz (Insight Biotechnology Ltd, Middlesex, UK) respectively. 
Horseradish peroxidase (HRP) conjugated donkey anti-rabbit and donkey anti-mouse 
secondary antibodies were from Santa Cruz. PD98059, U0126 (MEK/ERK inhibitors) and 
SB203580 (p38 inhibitor) were from Cell Signalling Technology. 
Cell Isolation, Culture and Ethics 
Keratinocytes and dermal fibroblasts were derived from anonymised healthy volunteers 
undergoing cosmetic surgery with informed consent, local research ethics approval (Ethical 
Tissue, University of Bradford).  Skin samples were processed on the day of collection. 
Fibroblasts were isolated by placing the trypsinized dermis in a T75 culture flask; ensuring 
the upper layer just below the epidermis adhered firmly to the flask. 10 ml DMEM containing 
10% FBS was carefully added to the flask so as not to allow the dermis to float. Fibroblasts 
explanted after 5 to 7 days. Full details in supplementary information. 
 
Cell Stimulation 
Keratinocytes or fibroblasts were seeded into 24-well or 6-well and allowed to grow to ~ 80% 
confluency. For keratinocytes, culture medium was replaced with KGM without human 
epidermal growth factor and hydrocortisone (KGM -/-) prior to cell treatment with cytokines. 
Dermal fibroblasts were starved of serum for 24 hour before treatment in serum-free DMEM. 
For inhibition experiments, cells were pre-treated for 1 hour with 10 μM SB203580 (Cell 
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signalling), 30 μM PD98059 or 10 μM U0126 (Cell signalling) before treatment with IFNα or 
IFNλ1. Controls included untreated cells and cells treated with dimethylsulphoxide vehicle 
(DMSO), SB203580 or PD98059/U0126 alone for 24 hours. 
Quantitative RT-PCR 
MxA, GBP-1, OAS2, IFI-16, CXCL9, IFNλR1, Col1A1, Col3A1, Col4A2 and Col7A1 
QuantiTect primer assays were obtained from Qiagen (Hilden, Germany) while U6 primer 
(forward – 5’ CTCGCTTCGGCAGCACA 3’; reverse-5’ AACGCTTCACGAATTTGC 3’) was 
purchased from Sigma Aldrich, UK. The following parameters were used: Initial heat 
activation, 95oC for 5 minutes; denaturation, 95oC for 10 seconds; combined annealing and 
elongation, 60oC for 30 seconds for a 40 cycle run.  Data were analysed using the delta-
delta ct method. mRNA expression of each gene of interest was normalised to U6 SnRNA 
housekeeping gene. 
Agarose gel electrophoresis 
qPCR products were run at 40 mA for 30 minutes on 2% agarose gel. Image was taken 
under ultraviolet (UV) light. Full details in supplementary information. 
 
Western blotting 
Cells were lysed with CelLytic M lysis buffer (Sigma-Aldrich) containing protease inhibitor 
cocktail (Roche Applied Bioscience, Rotkreuz, Switzerland) and phosphatase inhibitor 
(Thermo Scientific). 30 µg of total protein was separated on any kDa mini protean gel 
(BioRad) and proteins were blotted onto 0.2 μm PVDF trans-blot pack (Bio-Rad). 
Membranes were probed with rabbit anti-human pSTAT1 (1:1000), STAT1 (1:1000), 
phospho p38 (1:1000), mouse anti-human pERK (1:2000), p38 (1:1000) or GAPDH (1:3000) 
in TBST containing 5% bovine serum albumin (BSA) overnight at 4oC. Rabbit anti-human 
MxA (1:1000), IFNλR1 (1:1000) and GAPDH were used in 5% milk PBST overnight at 4oC. 
Donkey anti-rabbit and donkey anti-mouse HRP-conjugated secondary antibodies were used 
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at 1:5000 and 1:3000 respectively for 1 hour at room temperature. For a repeat Western, 
membranes were stripped, blocked and re-probed with primary antibody.    
Cell trace proliferation assay 
Human primary keratinocytes and dermal fibroblasts were stained in KGM or serum-free 
DMEM respectively with cell trace violet (Molecular probes/Life technologies) away from the 
source of light (2 µl cell trace to 1 million cells in 1 ml media). Cells were plated in 6 well 
plates and were either treated with cytokines or untreated for 72 hours.  Some cells were 
used for the day 0 analysis. For flow cytometric analysis, a BD LSRFortessa (BD Bioscience, 
Oxford, UK) machine was used. Cell proliferation was calculated using ModFit software 
version 3.2 (Verity Software House, Topsham, ME. USA). Full details in supplementary 
information. 
Statistical analysis 
Statistical significance was determined using Mann Whitney test or unpaired t-test. Analysis 
was performed using GraphPad Prism software (GraphPad Software Inc. La Jolla, CA, 
USA). All data are expressed as means ± SEM and values of p < 0.05 were considered 
significant.  ‘n’ represents independent experiments; *p< 0.05, **p< 0.01. 
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Figure legends 
 
1. IFNλR1 expression and production in human dermal fibroblasts 
Cultured human dermal fibroblasts were either untreated or treated with 10 ng/ml 
IFNα for 4 or 16 hours in serum-free medium for mRNA and protein expression 
respectively. mRNA expression was measured using qPCR and protein by Western 
blotting and flow cytometry. (a) qPCR products for IFNλR1 and the housekeeping 
gene U6snRNA on 2% agarose gel are shown as a representative experiment out of 
five independent experiments (b) Relative mRNA expression; n=5 (c) Western blot 
analysis of IFNλR1 protein (d) protein band intensity; n=3 (e) flow cytometry. For 
statistical analysis, Mann Whitney U test was used to compare columns. Values 
represent mean ± SEM.  *p<0.005, **p<0.01. UT: Untreated; K: keratinocytes. 
 
 
2. ISGs expression in human skin resident cells 
Cultured dermal fibroblasts were either untreated or treated with 10 ng/ml IFNα or 
100 ng/ml IFNλ1 for 4 or 24 hours in serum-free medium. Primary keratinocytes were 
treated with the same concentration of cytokines for 6 or 24 hours in KGM (-/-). 
mRNA expression of ISGs was measured using qRT-PCR. a to d show expression 
levels in fibroblasts (a) MxA, 4 hours (b) MxA, 24 hours (c) GBP-1, 4 hours (d) GBP-
1, 24 hours . e to h show expression levels in keratinocytes  (e) MxA, 6 hours (f) 
MxA, 24 hours (g) GBP-1, 6 hours (h) GBP-1, 24 hours. For statistical analysis, Mann 
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Whitney U test was used to compare columns. n=5, values represent mean ± SEM.  
*p<0.005, **p<0.01. 
 
3. IFNλ1 induced STAT1 and MAPKs phosphorylation fibroblasts and 
keratinocytes 
Cultured human dermal fibroblasts (3a) or primary keratinocytes (3b) were either non 
treated or treated with 10 ng/ml IFNα or 100 ng/ml IFNλ1 for 10, 30 or 60 minutes. 
Total and phosphorylated p38, ERK and Stat1 along with GAPDH were detected by 
Western Blot.  A representative out of three independent experiments with cells from 
different donors is depicted. UT: untreated. 
 
4. Inhibition of MxA production by phospho- p38 and -ERK inhibitors 
Cultured dermal fibroblasts or primary keratinocytes were either untreated or treated 
with MAPK inhibitors or IFNs for 4 and 24 hours and MxA was detected on the 
mRNA level and by Western blot (24 hours only). (a) MxA mRNA expression, 4 
hours; n=3 (b) MxA mRNA expression, 24 hours; n=3 (c) MxA protein expression by 
IFNλ1 in the presence or absence of MAPK inhibitors in fibroblasts (d) MxA protein 
expression by IFNα in the presence or absence of MAPK inhibitors in fibroblasts (e) 
MxA protein expression by IFNλ1 and IFNα in human primary keratinocytes in the 
presence or absence of MAPK inhibitors. Figures are representative of three 
independent experiments. SB: SB203580 (p38 inhibitor); U: U0126 (MEK/ERK 
inhibitors).  
 
5. Effect of IFNλ of collagen expression in human dermal fibroblasts 
Cultured dermal fibroblasts were either untreated or treated with 10 ng/ml IFNα, 100 
ng/ml IFNλ1, 5 ng/ml TGFβ1 or combination of IFNλ1 and TGFβ1 for 24 hours. 
mRNA expression of ISGs was measured using qRT-PCR. Depicted is Col1A1 (a)  
Col3A1 (b) Col4A2 (c) and Col7A1 (d) expression. For statistical analysis, Mann 
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Whitney U test was used to compare columns. n=5, values represent mean± SEM.  
*p<0.005, **p<0.01. 
 
6. Effects of IFNs on proliferation of skin resident cells 
Human dermal fibroblasts or primary keratinocytes labelled with cell tracer violet in 
DMEM containing 1% FBS and KGM respectively. Plated cells were either untreated 
or treated with cytokines. Daughter cell populations (different colours) of dividing cells 
were visualised by flow cytometric analysis after 72 hours of stimulation. (a) Cell 
tracer dependent fluorescent signal in keratinocytes at 0 hour and after 72 hours of 
stimulation. (b) Percentage proliferation of keratinocytes after 72 hours (c) cell tracer 
dependent fluorescent signal in fibroblasts at 0 hour and 72 hours after stimulation. 
(d) Percentage proliferation of fibroblasts after 72 hours. For statistical analysis, 
unpaired t test was used to compare columns; n=3 and values represent mean± 
SEM.  *p<0.005, **p<0.01. 
 
 
 
 
 
